Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

EndoMed Thoracic Stent Graft Requires Separate IDE – FDA Warning Letter

This article was originally published in The Gray Sheet

  • News

Executive Summary

EndoMed envisions a late summer European launch for its pre-loaded aortomonoiliac and thoracic Endofit endoluminal stent grafts

You may also be interested in...



Medtronic Tests Talent For U.S. Thoracic Aortic Aneurysm Market

Medtronic is projecting that its Talent thoracic aortic aneurysm (TAA) endovascular stent graft system will gain premarket approval in late 2005

Medtronic Tests Talent For U.S. Thoracic Aortic Aneurysm Market

Medtronic is projecting that its Talent thoracic aortic aneurysm (TAA) endovascular stent graft system will gain premarket approval in late 2005

Endomed Plans To Re-Launch AAA Device In Europe, Following MDA Alert

Patient deaths related to Endomed, Inc.'s Endofit endoluminal aortic stent graft resulted from errors made by physicians who did not follow device instructions, the Phoenix-based company maintains

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT018657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By